NASH Opportunity Spurs Deal-Making Flurry
Executive Summary
Companies big and small are making deals and advancing candidates to address an unmet medical need thought to have a vast undiagnosed patient base in the U.S. and Europe.
You may also be interested in...
Deal Watch: Gilead’s Move Into NASH Highlights Post-Holiday Deal-Making
Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.